ERY-974

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameERY-974
Drug Alias NameERY-974
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers
Mechanisms of ActionCD3 T-cell engagersGlypican-3 inhibitorsWnt signalling pathway inhibitors
TargetsGlypican-3T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A